CervoMed is trading 5.7% up in pre-market at $2.42, with positive initial Phase 2a biomarker data as context. - October 20 close: $2.29; no October 21 company announcement appeared in search results. - Neflamapimod data, reported October 19 and updated October 20, showed reduced mean plasma neurofilament light in the first 12 weeks. H.C. Wainwright reiterated Buy and a $25 target. - Markets were positive, but index moves don’t establish market sentiment as the cause; no volume data was provided.